Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis
Canadian Medical Association Journal · 2024
DOI: 10.1503/cmaj.240787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Medical Association Journal, 2024. Verfasst von Mélanie Drolet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche du CHU de Québec - Université Laval (Drolet, Laprise, Chamberland, Sauvageau, Brisson); Département de médecine sociale et préven…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Models, Theoretical. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Worldwide, countries are examining whether to implement 1-dose human papillomavirus (HPV) vaccination instead of using 2 doses. To inform policy, we sought to project the population-level impact and efficiency of switching from 2-dose to 1-dose gender-neutral routine HPV vaccination in Canada. METHODS: We used HPV-ADVISE, an individual-based transmission-dynamic model of HPV infections and diseases, to mathematically model vaccination programs in 2 provinces, Quebec, a province with high HPV vaccination coverage (around 85%), and Ontario, which has lower coverage (around 65%). We examined non-inferior and pessimistic scenarios of the efficacy (vaccine efficacy of 98% or 90%) and average vaccine duration (lifelong, 30 yr, or 25 yr) of 1 dose compared with 2 doses (98% vaccine efficacy, lifelong vaccine duration). Our main outcomes were the relative reduction in HPV-16 (by sex) and cervical cancers, and the number of doses needed to prevent 1 cervical cancer. RESULTS: Our model projected that 1-dose HPV vaccination would avert a similar number of cervical cancers as 2 doses in Canada, under various scenarios. Under the most pessimistic scenario (25-yr vaccine duration), 1-dose vaccination would avert fewer cervical cancers than 2 doses, by about 3 percentage points over 100 years. All 1-dose scenarios were projected to lead to elimination of cervical cancer ( 10 000 doses needed to prevent 1 additional cervical cancer). INTERPRETATION: If the average duration of 1-dose protection is longer than 25 years, a 1-dose HPV vaccination program would protect those vaccinated during their peak ages of sexual activity and prevent a similar number of HPV-related cancers as a 2-dose program, while being a more efficient use of vaccine doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de recherche du CHU de Québec - Université Laval (Drolet, Laprise, Chamberland, Sauvageau, Brisson); Département de médecine sociale et préventive (Sauvageau, Brisson), Université Laval; Institut national de sant…
Zitieren
APA
Drolet, M., Laprise, J. F., Chamberland, É., Sauvageau, C., Wilson, S., Lim, G. H., Ogilvie, G., Tuite, A., & Brisson, M. (2024). Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.240787
Vancouver
Drolet M, Laprise JF, Chamberland É, Sauvageau C, Wilson S, Lim GH, et al. Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis. Canadian Medical Association Journal. 2024. doi:10.1503/cmaj.240787
BibTeX
@article{Drolet2024,
author = {Drolet, Mélanie and Laprise, Jean-François and Chamberland, Éléonore and Sauvageau, Chantal and Wilson, Sarah and Lim, Gillian H and Ogilvie, Gina and Tuite, Ashleigh and Brisson, Marc},
title = {Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis},
journal = {Canadian Medical Association Journal},
year = {2024},
doi = {10.1503/cmaj.240787}
}
EUVIMED